[A20-124] Nintedanib (interstitial lung disease) - Addendum to Commission A20-71
Last updated 04.02.2021
Project no.:
A20-124
Commission:
Commission awarded on 22.12.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Indication:
Adults with chronic progressive fibrosing interstitial lung diseases other than SSc-ILD or IPF
Result of dossier assessment:
Still indication of minor added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-71 | Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-02-04: A G-BA decision was published